EGFR and non-small cell lung carcinoma: It displayed distinct binding mode, proper drug like properties, potentially better safety window as well as potent in vitro and in vivo efficacies against EGFR mutants driven NSCLC preclinical models, which makes it a potential useful clinical candidate.